302 related articles for article (PubMed ID: 15182339)
1. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
[TBL] [Abstract][Full Text] [Related]
4. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
5. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.
Baudard M; Vincent A; Moreau P; Kergueris MF; Harousseau JL; Milpied N
Bone Marrow Transplant; 2002 Sep; 30(5):287-95. PubMed ID: 12209350
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
Miyoshi T; Kawano-Yamamoto C; Nagashima T; Nagai T; Komatsu N; Muroi K; Ozawa K
Rinsho Ketsueki; 2003 Sep; 44(9):968-70. PubMed ID: 14577320
[TBL] [Abstract][Full Text] [Related]
11. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
Iida M; Fukuda T; Uchida N; Murata M; Aotsuka N; Minagawa K; Oohashi K; Fukushima K; Kondo T; Eto T; Miyamoto T; Morishima Y; Nagamura T; Atsuta Y; Suzuki R
Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
[TBL] [Abstract][Full Text] [Related]
16. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.
Onishi C; Ohashi K; Sawada T; Nakano M; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Int J Hematol; 2010 Apr; 91(3):464-70. PubMed ID: 20217287
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.
Mookerjee B; Altomonte V; Vogelsang G
Bone Marrow Transplant; 1999 Sep; 24(5):517-20. PubMed ID: 10482936
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation.
Hambach L; Stadler M; Dammann E; Ganser A; Hertenstein B
Bone Marrow Transplant; 2002 Jun; 29(11):903-6. PubMed ID: 12080355
[TBL] [Abstract][Full Text] [Related]
20. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]